Safety of infliximab use during pregnancy

Djokanovic, Nada; Klieger-Grossmann, Chagit; Pupco, Anna; Koren, Gideon

doi:10.1016/j.reprotox.2011.05.009

Cited by 64 publications

(43 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TNFα antagonist exposure during early pregnancy may be less concerning since placental transfer of IgG antibodies is minimal during the first trimester, but placental transfer of IgG antibodies does become more efficient as pregnancy progresses, with case reports showing that infliximab is present in neonatal serum if the mother has been treated during the third trimester (Djokanovic et al 2011). …”

Section: Tnfa Antagonistsmentioning

confidence: 99%

Corticosteroids and Anti-Complement Therapy in Retinal Diseases

Narayanan

Kuppermann

2016

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

Section: Tnfa Antagonistsmentioning

confidence: 99%

Corticosteroids and Anti-Complement Therapy in Retinal Diseases

Narayanan

Kuppermann

2016

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

“…According to a few studies, when infliximab was given during the third trimester, it was detected in the infant's blood [37,39]. However, it did not predispose the infants to a higher risk of infections, with the exception of one report of disseminated mycobacterial infection in an infant whose mother was given infliximab during pregnancy and the infant received BCG vaccine at 3 months of age.…”

Section: Biologic Immune Modifiersmentioning

confidence: 99%

“…If infliximab is administered to a pregnant patient, it should be given during the first 30 weeks of pregnancy and resumed after delivery. Vaccinations with live viruses should be postponed in these infants until they are at least 6 months old [34,39].…”

Section: Biologic Immune Modifiersmentioning

confidence: 99%

Safety of Common Medications for Treating Dermatology Disorders in Pregnant Women

Malka

Ziv

2013

Curr Derm Rep

View full text Add to dashboard Cite

Treating the pregnant woman poses challenges to the physician that requires balancing between eliminating or alleviating a condition or disease and ensuring no untoward effects on the mother and fetus. Despite the importance of the task, human studies are limited for obvious reasons, and animal studies do not fully resemble human physiology. Nevertheless, thanks to epidemiology studies and large-scale reviews of case reports on pregnant patients with comorbidities or refractory diseases that necessitate treatment with drugs of uncertain safety, data are accumulating on the safety of medications during pregnancy. This review summarizes the current literature on the safety during pregnancy of medications frequently used for common dermatologic diseases. The goal is to provide physicians with a handy database for when to, and when not to, prescribe those medications.

show abstract

“…Data regarding safety of the antibodies use during pregnancy and fetal outcomes are limited. In most studies investigating Infliximab and Adalimumab [33,34,36,38] no increased risk of teratogenicity or adverse pregnancy outcome was observed, but contradictory data exist [39]. A recently published small cohort main topic wmw 9-10/2012 Ó Springer-Verlag Ellinger and Fuchs -Placental IgG transport prospective study found no adverse events of Natalizumab on pregnancy outcomes in humans [40].…”

Section: Transplacental Transport Of Therapeutic Antibodiesmentioning

confidence: 99%

HFcRn-mediated transplacental immunoglobulin G transport: Protection of and threat to the human fetus and newborn

Ellinger

Fuchs

2012

Wien Med Wochenschr

View full text Add to dashboard Cite

In human newborns, endogenous levels of plasma immunoglobulin G (IgG) begin to rise slowly after birth following exposure to the environment. For immunoprotection during fetal and early neonatal life, maternal IgG is provided by transplacental transport. While cellular immunoprotective IgG effects are mainly triggered by FcγRI, -RII and -RIII, transplacental IgG transfer is mediated by the MHC class I-like neonatal Fc-receptor, hFcRn. This compact review explains the mechanism of hFcRn-mediated IgG transcytosis across the placental barrier - syncytiotrophoblast and fetal endothelial cells. Restrictions of this IgG transport are summarized. These include IgG subclass discrimination and limited IgG transport before the third trimester that can cause insufficient protection from infections of preterm (≤ 35 th week) delivered babies. As hFcRn does not discriminate beneficial from hazardous IgGs, maternal auto- and alloimmune as well as therapeutic antibodies can reach the fetus. The consequences including severe diseases of the newborn are summarized in this article.

show abstract

Safety of infliximab use during pregnancy

Cited by 64 publications

References 23 publications

Corticosteroids and Anti-Complement Therapy in Retinal Diseases

Corticosteroids and Anti-Complement Therapy in Retinal Diseases

Safety of Common Medications for Treating Dermatology Disorders in Pregnant Women

HFcRn-mediated transplacental immunoglobulin G transport: Protection of and threat to the human fetus and newborn

Contact Info

Product

Resources

About